These slides were presented at the recent IHS webcast: The Impact of AMNOG on Global Market Access Strategies on 28 June 2011.
In this webcast we examined the German healthcare reform and what it means for the global pharmaceutical industry.
• The impact of the reform on national and global market access strategies for medicines subject to early benefit assessment
• How the reform may impact your clinical trial development
• How innovative the reform is from an international perspective